Role of 68Ga-Labelled PSMA PET/CT in Assessment and Staging of Prostate Cancer

Background Prostate cancer (PCa) is the most common worldwide tumor in men with increasing incidence. Aim of the Work The purpose of our study is to evaluate the potential role of 68Ga-labelled PSMA PET/CT in assessment and staging of prostate cancer and correlate those positive findings with biopsy. Patients and Methods Thirty patients with pathologically confirmed prostate cancer who underwent PET/CT study. They were selected from Department of Radiology at Ain Shams University Hospital from November 2020 to May 2021. The patients’ ages ranged between 53 and 89 years old (mean age 66.43 ± 8.9 years). All patients underwent a 68Ga-PSMA PET/CT examination. For each patient, we determined the disease stage, the Gleason score, and the maximum standardized uptake value (SUVmax) for primary prostatic tumor and extraprostatic metastases. The diagnostic sensitivity and specificity of 68Ga-PSMA PET/CT for diagnosis and staging of PC were established by histopathology as the reference standard. Results Median SUVmax for the primary tumor was 12.88 (range, 6.7–25). Nineteen patients had associated PSMAavid lymph nodes, median SUVmax for those was 11 (range, 3.7–29). 68Ga-PSMA PET/CT detected extraprostatic metastases in 19 (63.3%) patients. The most common site of extraprostatic metastases was the bone (17 patients). The sensitivity of 68Ga-PSMA PET/CT examination in the diagnosis of PC was 90.9% and specificity was 68.4%. Conclusion 68Ga-PSMA PET/CT is a valuable tool with high diagnostic sensitivity and good specificity for diagnosis and staging of patients with newly diagnosed PC.